Last reviewed · How we verify

NCT05925686

Tramadol to Improve Its Detection in Biological Matrices in Anti-doping Controls

Completed Phase 1 Last updated 3 November 2023
What this trial tests

Phase 1 trial testing Tramadol. in Healthy in 25 participants. Completed in 17 October 2023.

Timeline
1 June 2023
Primary endpoint
11 October 2023
17 October 2023

Quick facts

Lead sponsorParc de Salut Mar
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment25
Start date1 June 2023
Primary completion11 October 2023
Estimated completion17 October 2023
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Parc de Salut Mar — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers will be administered with the objective to evaluate urine and blood concentrations in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Parc de Salut Mar trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05925686.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing